Previous 10 | Next 10 |
Lung cancer diagnostics company, Biodesix (BDSX) has priced initial public offering of ~4.17M common shares at $18/share.Underwriters' over-allotment is an additional 600K shares.Trading commences today on Nasdaq.Offering is expected to close on October 30.Net proceeds of ~$30M will be u...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020. In conjunction with the release, the Company will host a conference call and webcast...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Gainers: [[ALGS]] +17.2%. [[FLDM]] +11.1%. [[SELB]] +9%. [[SOS]] +5.2%. [[PSNL]] +4%.Losers: [[TCOM]] -8.5%. [[FISV]] -6%. [[SCS]] -5.4%. [[LOOP]] -5.4%. [[AGIO]] -4.4%. For further details see: FISV, TCOM, FLDM and SELB among after-hours movers
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020. Personalis will present “Maximizing immunotherapy biomarke...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at IO Combinations 360˚ which will be held online, October 1-2, 2020. The presentation, titled “Comprehensive immunogenomics to enable comp...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Digital World CB & CDx meeting which will be held online, September 29-October 1, 2020. Personalis will present “Enabling the Expansive...
A resistance line has formed in the chart of Personalis (PSNL). As the stock test its high, look for a breakout. Learn when to enter a long position. Shares of Personalis ( PSNL ) could see a strong move higher soon. That’s because a key resistance level has formed on the sto...
Personalis (NASDAQ: PSNL ) has announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend its existing contract through September 2021. More news on: Personalis, Inc., Healthcare stocks news, Read more ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announces that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has exercised its option to extend our existing contract through September 2021. The VA also issued a ne...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...